Skip to content
Review

Alzheimer’s Disease: From Molecular Pathogenesis to Disease-Modifying Therapies and Clinical Implementation in Aging Populations

· 0 citations · 216 references

TL;DR

This comprehensive review synthesizes current knowledge across the full spectrum of AD, encompassing molecular pathophysiology (amyloid cascade, tau hyperphosphorylation, and neuroinflammation), genetic architecture, genetic architecture (familial mutations and APOE-mediated risk), evolving biomarker-based diagnostic frameworks, established symptomatic treatments, and newly approved disease-modifying agents.

View source

Similar papers

Review Open access Oct 2026

Rapidly Progressive Alzheimer’s Disease: Candidate Mechanisms and Diagnostic Challenges

Abstract Alzheimer’s disease (AD) usually follows a slowly progressive course, but some patients experience unusually rapid cognitive and functional decline. This clinical phenotype, commonly termed rapidly progressive Alzheimer’s disease (rpAD), has no consensus definition; its status as a distinct biological entity r...

Mei-Ling Cao, Lu-Ming Leng, Ping Liu et al. · 0 citations
Review Open access Sep 2026

Translating Molecular Pathogenesis into Therapeutics: Emerging Strategies and Clinical Prospects for Alzheimer’s Disease

Alzheimer’s disease (AD) is a devastating neurodegenerative disorder that affects millions of people worldwide and poses a major global health challenge. This complex disease involves multiple pathogenic factors, including amyloid-beta (Aβ), tau protein aggregation, synaptic dysfunction, mitochondrial impairment, oxida...

Mona Piplani, Shivani Thakur, Pankaj Kumar et al. · 0 citations
Review Open access Oct 2026

Disease-modifying therapies in Alzheimer's disease: anti-amyloid monoclonal antibodies and clinical perspectives

Background: Alzheimer's disease is characterized by progressive cognitive decline and the accumulation of beta-amyloid and neurofibrillary tangles in the brain. Traditionally, treatments have only been symptomatic, but anti-amyloid monoclonal antibodies, such as lecanemab and donanemab, are emerging as therapies capabl...

Isabella Motta Melo, Isadora Silveira Ralin, M. Corcinio · 0 citations
Review Open access Sep 2026

Understanding Alzheimer's disease through biomarkers: pathology, progression, and clinical application.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide accounting for an estimated 60% to 80% of cases. Biomarkers play an integral role in AD randomized clinical trials (RCTs), providing objective measures of disease pathology, progression, and therapeutic effi...

Xiao-Lan Zhang, Michael F. Murphy, Henry J. Riordan et al. · 0 citations
Review Open access 2026

Immunotherapeutic Strategies Targeting Amyloid-β and Tau in Alzheimer’s Disease: A Systematic Review of Clinical Efficacy, Safety, and Translational Limitations

Alzheimer’s disease (AD) is one of the leading neurodegenerative disorders affecting over 55 million individuals worldwide, with a limited selection of disease-modifying therapies. The amyloid cascade hypothesis proposes that amyloid-beta (Aβ) peptide accumulation initiates a cascade of synaptic dysfunction, neuroinfla...

R. Menon · 0 citations
#federated learning Open access Oct 2026

Integrating cure and care in Alzheimer’s disease: a systems perspective for precision medicine

Alzheimer’s disease remains a major global health challenge, with limited disease-modifying therapies and a rapidly growing societal burden. Although amyloid and tau remain central to the field, current evidence also implicates neuroinflammation, immune dysregulation, vascular dysfunction, and host-microbe interactions...

J. A. Rice, Jean-Marie C. Bouteiller, A. Khachaturian · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.